CCL25 and myeloid sarcoma: This indicates CCL25 as a risk factor for MS, which is revealed in this study as well (OR: 1.085, 95% CI: 1.011–1.165, p = 2.42 × 10−2, adjusted p_adj_bon = 1, p_adj_fdr = 0.307) and suggests its potential as a biomarker and therapeutic target of MS.